DIN 02370069 — BENLYSTA 400 MG
BENLYSTA is a powder for solution of Belimumab marketed by GLAXOSMITHKLINE INC. The full Belimumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02370069
- Brand name
- BENLYSTA
- Active ingredient
- Belimumab
- Strength
- 400 MG
- Dosage form
- POWDER FOR SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- GLAXOSMITHKLINE INC
- Health Canada status
- MARKETED
- Drug class
- BLyS-specific inhibitor (selective immunosuppressant)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Belimumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02370050 | BENLYSTA | 120 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED |
| 02470489 | BENLYSTA | 200 MG | SOLUTION | GLAXOSMITHKLINE INC | MARKETED |